Naproxen free acid received as veterinary active pharmaceutical ingredient is milled to a target D90 below 150 µm before blending in solid oral dosage lines. Unmilled material exhibits angle of repose above 40° and requires forced-feed hoppers or granulation to avoid rat-holing in rotary tablet presses. Sodium salt variants, where regional veterinary authorisations permit, display pH-dependent aqueous solubility sufficient for injectable preparation but increase hygroscopicity at relative humidity above 60%. Processing suites handling milled free acid are maintained under ISO 14644-1:2015 Class 8 at minimum, with local dust extraction at weigh booths. Batch-to-batch variability in particle size distribution, particularly D10 below 5 µm, creates segregation risks in low-dose blends because fines migrate to the bottom of hoppers during transfer. Loss-on-drying specifications for incoming API are set at 0.5–1.0% w/w according to USP <731>; variation outside this range alters granulation water demand and increases tablet hardness drift. Sieve analysis of milled naproxen after 20-mesh screening is used to reject agglomerates before lubrication. Magnesium stearate is added at 0.5–1.5% w/w but only after the API has been pre-blended to avoid hydrophobic film formation that retards dissolution. Elemental impurities are controlled under ICH Q3D(R2) with limits derived from veterinary dose and body weight, and residual solvents under ICH Q3C(R8) mirrored by VICH GL18. For enteric or delayed-release tablet cores, the free acid dissolution is strongly pH-dependent; in vitro release at pH 1.2 may be below 10% in 2 hours, shifting the dissolution test toward a two-stage method with pH 6.8 buffer after the acid stage. Published data for this specific configuration is limited, so formulators should confirm saturation solubility at 4 °C, 25 °C, and 40 °C before committing to registration batches.

How Does Wet Granulation Endpoint Control Reduce Tablet Capping and Lamination?

Wet granulation is deployed for naproxen tablet cores because the free acid exhibits poor compactability under direct compression, leading to capping at main compression forces above 12 kN. The process uses a high-shear granulator with main impeller tip speed in 4–8 m/s and chopper speed 1,500–3,000 rpm; endpoint is controlled by impeller power draw or torque rather than fixed granulation time. Granule moisture at discharge is held at 1.5–3.0% w/w because lower moisture produces brittle granules with fine particle tails, while higher moisture causes sticking to drying trays and increases residual solvent burden. Drying in a fluid-bed dryer with inlet air temperature 50–70 °C is terminated when outlet air temperature reaches 40–45 °C; final LOD is verified by USP <731>. Milled granules are blended with crospovidone at 2–5% w/w and microcrystalline cellulose as diluent, then compressed on a rotary press equipped with precompression station at 4–8 kN and main compression at 12–20 kN using 10 mm round tooling. Tablet hardness is monitored to 60–100 N under USP <1217>; hardness below 50 N correlates with edge chipping during coating, while hardness above 110 N increases disintegration time beyond 15 min in pH 6.8 phosphate buffer. Dissolution is evaluated under USP <711> Apparatus II at 50 rpm; Q values are established by regional veterinary marketing authorisations, not by compendial default. Content uniformity follows USP <905> with acceptance value ≤15 for low-dose strengths. Residual solvent levels are controlled under ICH Q3C(R8) and USP <467>; isopropyl alcohol, if used in granulation, is limited to Class 3 concentration limits. Aqueous film coating is performed at pan speed 5–8 rpm and inlet air temperature 55–65 °C; coating weight gain of 3–5% w/w is used for taste masking in canine tablets. Coated tablets are stored in high-density polyethylene containers with desiccant because naproxen sodium absorbs moisture above 60% RH, causing surface pitting and dissolution slowdown.

In terminal sterilisation of aqueous naproxen sodium solutions, pH drift during autoclaving remains the primary cause of batch rejection. The sodium salt is dissolved in water for injection at a concentration equivalent to naproxen 20–50 mg/mL, and the pH is adjusted to 8.0–9.5 using sodium hydroxide because free acid precipitation occurs rapidly below pH 7.5. Terminal sterilisation by moist heat at 121 °C for 15 min is limited by the chemical stability window; above pH 9.5, degradation rate increases and solution colour deepens. Sterile filtration through 0.22 µm polyvinylidene fluoride membranes is preferred for heat-sensitive formulations, followed by aseptic filling in an ISO 5 zone under ISO 14644-1:2015. Type I borosilicate glass vials conforming to USP <660> are used because alkaline solutions above pH 9.0 can extract surface aluminium and silicon from Type III soda-lime glass. Elastomeric closures are screened for extractables under USP <381>; sulfur-cured butyl stoppers may release leachables into alkaline naproxen sodium solutions during long-term storage at 25 °C. Microbial quality is verified by USP <71> sterility testing and USP <85> bacterial endotoxins with a limit calculated from maximum daily veterinary dose. Antioxidant sodium metabisulfite at 0.05–0.2% w/v may be added but can react with container closure elastomers; nitrogen sparging during filling is an alternative control for oxygen headspace. Benzyl alcohol is excluded from feline injectable formulations because of documented toxicity; this restriction affects multi-dose presentations. The solution is protected from light in amber glass because naproxen sodium undergoes photodegradation under ICH Q1B conditions. Published data for terminal sterilisation of naproxen sodium aqueous solutions at veterinary injection volumes is limited; thermal stability evaluation should be run before selecting a sterilisation cycle.

Capsule Fill Weight Deviations and Powder Bridging in Semi-Automatic Encapsulators

Capsule filling of naproxen-containing blends on semi-automatic equipment is sensitive to powder bed depth, auger speed, and hopper vibration. Granulated material with bulk density 0.45–0.65 g/mL and Carr index 15–25% provides acceptable fill weight variation, while unmilled API with Carr index above 30% causes bridging at the dosing disk and weight deviations exceeding ±5%. Gelatin and hypromellose capsule shells are conditioned to 13–16% moisture content; drying below 12% increases shell brittleness on high-speed filling lines, while moisture above 18% leads to softening and deformation. Fill weight is monitored gravimetrically every 15 minutes during production; acceptance limits for individual capsule weight variation follow USP <905> where applicable. For low-dose strengths, a pre-blend of naproxen and lactose monohydrate in a 1:10 ratio is prepared before final dilution to reduce segregation. Dissolution of capsule contents is tested in pH 7.4 phosphate buffer using USP <711> Apparatus I at 100 rpm because capsule shells delay rupture by 3–5 min. Cross-linking of gelatin shells due to peroxide-containing excipients is avoided by controlling fill excipient peroxide value below 10 meq/kg; hypromellose shells are selected for moisture-sensitive formulations. Equipment cleaning validation for naproxen is verified by swab sampling with high-performance liquid chromatography limit of quantification below 0.1 ppm or region-specific permitted daily exposure. On continuous production lines, metal detection is performed after encapsulation with test spheres of 0.8 mm ferrous, 1.2 mm non-ferrous, and 1.5 mm stainless steel. Powder bridging in the feed screw is mitigated by vibratory feeding at amplitude 0.5–1.0 mm and frequency 50–80 Hz; hopper relative humidity is maintained below 50% RH to prevent naproxen sodium surface wetting.

For equine oral powders and non-food animal premises, naproxen incorporation into dry carriers such as dextrose or apple-flavoured maltodextrin requires particle size overlap between API and carrier to prevent segregation during transit. A geometric dilution sequence is used: API is first blended with an equal mass of carrier for 10 minutes in a V-blender at 25 rpm, then the mixture is diluted stepwise to final concentration. Coefficient of variation for active content is determined by sampling 10 stratified locations and should not exceed 5% under ISO 6497:2002 animal feeding stuffs sampling. Use in food-producing species is excluded in the European Union because naproxen is not listed in the positive list of Commission Regulation (EU) No 37/2010; any premix intended for slaughter-class animals or lactating dairy cattle would require national derogation and is not supported by this veterinary-grade API specification. Carryover limits in feed manufacturing equipment are based on toxicological risk assessment; cleanout between non-compatible medicated batches uses physical cleaning and, where validated, flushing with 10–20 kg of diluent per tonne mixer capacity. Microtracer addition is optional; when used, iron particle recovery is verified at 90–110% in finished feed. The API is dispensed into intermediate bulk containers with liner electrostatic dissipation; humidity is maintained below 60% RH because naproxen sodium absorbs moisture and forms agglomerates that do not disperse in dry mixing. Binary mixer studies on a twin-shell blender show that material with D90 above 200 µm can separate from fine carrier particles during discharge; the resulting active content variation in first and last sacks exceeds ±15% if not corrected by end-to-end recycling. Published data for this specific configuration is limited, so pilot-scale mixing trials are required before commercial release.

When Oral Solutions Require Viscosity Control Without Sacrificing Chemical Stability

Oral solutions and suspensions for companion animals require pH stabilisation because naproxen free acid has low aqueous solubility but naproxen sodium ionises rapidly below pH 5.0. Buffering with citrate or phosphate systems at pH 7.0–8.0 maintains solubility while avoiding the degradation seen above pH 9.0. Suspension formulations use xanthan gum at 0.2–0.5% w/v to achieve apparent viscosity 150–400 mPa·s measured on a Brookfield RVT viscometer at 20 rpm with spindle 3. Higher viscosity delays sedimentation but also prolongs reconstitution time after shaking; sedimentation volume after 72 hours should be above 0.9. Preservative efficacy testing follows USP <51> and Ph. Eur. 5.1.3; sodium benzoate at 0.1–0.2% w/v is used only when pH is below 8.0 because benzoate loses efficacy in alkaline systems. Sorbitol at 30–50% w/v masks bitterness but increases osmolality; this is acceptable for oral use but not for parenteral. Light protection is provided by amber polyethylene terephthalate bottles; photostability is assessed under ICH Q1B conditions. Syringeability through oral dosing syringes with tip orifice 1.2 mm is checked at 25 °C; formulations with particle size above 200 µm block or produce inconsistent dosing. The solution is not terminally sterilised; microbial quality follows USP <1111> acceptance criteria for nonsterile oral liquids. Small-volume administration to cats is generally avoided because naproxen has a narrow safety margin in this species; any feline label claim requires species-specific toxicity data. Published data for high-concentration naproxen oral solution beyond 100 mg/mL remains limited; formulators should conduct saturation solubility measurements at 4 °C, 25 °C, and 40 °C before committing to pilot registration batches.